| Bioactivity | BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ)-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway[1]. | ||||||||||||
| Target | L-type voltage-dependent Ca2+ channel/CaMK2 | ||||||||||||
| Name | BBT | ||||||||||||
| CAS | 445000-45-3 | ||||||||||||
| Formula | C18H12BrNO2S | ||||||||||||
| Molar Mass | 386.26 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Yao XG, et al. BBT improves glucose homeostasis by ameliorating 尾-cell dysfunction in type 2 diabetic mice. J Endocrinol. 2015 Mar;224(3):327-41. |